Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06649838
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-17
Brief Title:
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Immunotherapy is the main option for advanced recurrent and metastatic cervical cancer However due to the complex interaction between the immune system and tumors there is still a lack of effective markers for immunotherapy Scientists are actively searching for and developing new immunotherapy markers For cervical cancer diagnosis it has been shown that ctDNA mutations can reflect HPV integration sites In terms of cervical cancer prognosis monitoring cohort studies focused on the application of HPV ctDNA in the field of cervical cancer prognosis monitoring The aim of this study is to design a customized ctDNA probe for cancer patients through a priori tumor detection method and to guide recurrence monitoring plan and implement individualized adjuvant therapy according to the results and to explore personalized biomarkers to guide cervical cancer immunotherapy To explore the possibility of customized ctDNA detection as a diagnostic marker for cervical cancer To explore the predictive and prognostic value of customized ctDNA dynamic monitoring A multi-arm cohort clinical study is planned To comprehensively study the treatment strategy of advanced and recurrent cervical cancer and explore the related biomarkers through the customized dynamic monitoring of ctDNA in patients with advanced and recurrent cervical cancer A total of 60 patients with cervical cancer were enrolled
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None